東京大学医学部附属病院は、東京都文京区本郷七丁目にある東京大学医学部附属の大学病院。略称は東大病院。以前存在した同病院分院についても本記事内で解説する。

During the past decade, The University of Tokyo Hospital conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 12 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 9 clinical trials were completed. i.e. 81.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The University of Tokyo Hospital" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Boston Scientific Corporation" with 2 trials sponsored, "Ferring Pharmaceuticals" with 2 trials sponsored, "Janssen Pharmaceutical K.K." with 2 trials sponsored and "Japan Breast Cancer Research Network" with 2 trials sponsored. Other sponsors include 23 different institutions and companies that sponsored additional 32 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The University of Tokyo Hospital" #1 collaborator was "Kyowa Kirin Co., Ltd." with 2 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "Eidos Therapeutics, a BridgeBio company" with 1 trials as a collaborator and "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "The University of Tokyo Hospital" are "Heart Failure" (4 trials), "Breast Neoplasms" (2 trials), "Cervical Ripening" (2 trials), "Scleroderma, Systemic" (2 trials) and "Systemic Sclerosis" (2 trials). Many other conditions were trialed in "The University of Tokyo Hospital" in a lesser frequency.

Most popular intervention types in "The University of Tokyo Hospital" are "Drug" (28 trials), "Device" (6 trials), "Other" (5 trials), "Biological" (4 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Atezolizumab" (3 trials), "Bevacizumab" (3 trials), "Dinoprostone" (2 trials) and "burosumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "The University of Tokyo Hospital" are 34 trials for "All" genders, 6 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "The University of Tokyo Hospital". undefined are not yet recruiting, 6 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in The University of Tokyo Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in The University of Tokyo Hospital, 2 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".